Download PDF
Dtsch Med Wochenschr 2013; 138(23): 1212-1214
DOI: 10.1055/s-0033-1343209
Hämatologie und Onkologie | Commentary
Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie des fortgeschrittenen Hodgkin-Lymphoms

Treatment of advanced Hodgkin lymphoma
S. Kreissl
1   Klinik I für Innere Medizin, Universitätsklinikum Köln
,
P. Borchmann
1   Klinik I für Innere Medizin, Universitätsklinikum Köln
› Author Affiliations
Further Information

Publication History

Publication Date:
29 May 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Hodgkin-Lymphom - BEACOPPeskaliert - Brentuximab Vedotin

Keywords

Hodgkin lymphoma - escalated-dose BEACOPP - brentuximab vedotin
 

  • Literatur

  • 1 Behringer K, Mueller H, Goergen H et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013; 31: 231-239
    CrossrefPubMedGoogle Scholar
  • 2 Behringer K, Thielen I, Mueller H et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012; 23: 1818-1825
    CrossrefPubMedGoogle Scholar
  • 3 Borchmann P, Trelle S, Rancea M et al. First line treatment of advanced stage Hodgkin lymphoma with six cycles of BEACOPP escalated results in superior overall survival compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients. . 54th ASH Annual Meeting Abstracts, 2012
    PubMedGoogle Scholar
  • 4 Carde P, Karrasch M, Fortpied C et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. J Clin Oncol 2012; 30 Abstract 8002
    PubMedGoogle Scholar
  • 5 Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial). Lancet 2012; 379: 1791-1799
    CrossrefPubMedGoogle Scholar
  • 6 Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16: 888-897
    CrossrefPubMedGoogle Scholar
  • 7 Wongso D, Fuchs M, Plütschow A et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). Haematologica 2012; 17 Abstract 1111:457
    PubMedGoogle Scholar
  • 8 Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New Engl J Med 2010; 363: 1812-1821
    CrossrefPubMedGoogle Scholar
  • 9 Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189
    CrossrefPubMedGoogle Scholar